Literature DB >> 11576678

Novel vaccine strategies to T-independent antigens.

G B Lesinski1, M A Westerink.   

Abstract

T cell independent antigens do not require T cell help to induce an immune response, and are characterized by a lack of immunologic memory. These antigens can be divided into two classes, TI-1 or TI-2. TI-1 antigens, such as bacterial lipopolysaccharide, are potent B-cell mitogens, capable of non-specific, polyclonal activation of B cells. In contrast, TI-2 antigens can only activate mature B cells and consist of highly repetitive structures, such as capsular polysaccharides (CPS) from bacteria. Many vaccines currently in use consist of purified capsular polysaccharides from pathogenic bacteria such as Streptococcus pneumoniae and Neisseria meningitidis. These vaccines are efficacious in immune-competent adults, however, due to their TI-2 nature, are not effective in children <2 years of age. Converting polysaccharides into T cell dependent (TD) antigens, allows children, <2, to produce an effective immune response. This review focuses on various strategies used to convert the immune response to polysaccharide antigens from TI-2 to a TD response. Conjugate vaccines, anti-idiotypic antibodies, phage display library technology and DNA vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576678     DOI: 10.1016/s0167-7012(01)00290-1

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  36 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 3.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 4.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

5.  Phages harboring specific peptides that recognize the N protein of the porcine reproductive and respiratory syndrome virus distinguish the virus from other viruses.

Authors:  Xiaofeng Ren; Mingcui Wang; Jiechao Yin; Guangxing Li
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

6.  Conjugate-like immunogens produced as protein capsular matrix vaccines.

Authors:  Ann Thanawastien; Robert T Cartee; Thomas J Griffin; Kevin P Killeen; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-19       Impact factor: 11.205

7.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

Review 8.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

9.  A Leishmania infantum cytosolic tryparedoxin activates B cells to secrete interleukin-10 and specific immunoglobulin.

Authors:  Sofia Menezes Cabral; Ricardo Leal Silvestre; Nuno Moreira Santarém; Joana Costa Tavares; Ana Franco Silva; Anabela Cordeiro-da-Silva
Journal:  Immunology       Date:  2007-11-17       Impact factor: 7.397

10.  Anti-idiotypic antibodies: a new approach in prion research.

Authors:  Anja Colja Venturini; Maja Bresjanac; Tanja Vranac; Simon Koren; Mojca Narat; Mara Popović; Vladka Curin Serbec
Journal:  BMC Immunol       Date:  2009-03-19       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.